Brief: Wuxi Biologics Adds 69 Projects In Jan-April, Maintains Expected Revenue Growth
BRIEF-Wuxi Biologics Adds 69 Projects In Jan-April, Maintains Expected Revenue Growth May 31 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK:
SAYS ADDED 69 NEW PROJECTS IN JAN-APRIL, MAINTAINS EXPECTED REVENUE GROWTH OF 13-17% Y/Y
Further company coverage: 2269.HK
(Reporting by Beijing Newsroom)
((Ethan.Wang@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln